Bendamustine plus Rituximab Versus R‐CHOP as First‐Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study

BACKGROUND. Rituximab plus bendamustine (R‐B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R‐CHOP to R‐B in pati...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Mondello, Patrizia, Steiner, Normann, Willenbacher, Wolfgang, Cerchione, Claudio, Nappi, Davide, Mauro, Endri, Ferrero, Simone, Cuzzocrea, Salvatore, Mian, Michael
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: AlphaMed Press 2018
Onderwerpen:
Hematologic Malignancies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896707/
https://ncbi.nlm.nih.gov/pubmed/29317554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0037
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items